Alector (NASDAQ:ALEC) Stock Rating Upgraded by Wall Street Zen

Alector (NASDAQ:ALEC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other analysts also recently issued research reports about the company. BTIG Research upgraded Alector from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Morgan Stanley restated an “underweight” rating on shares of Alector in a research note on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alector in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $3.25.

Alector Stock Down 1.0%

NASDAQ ALEC opened at $1.99 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.76 and a current ratio of 3.76. The firm has a 50-day simple moving average of $1.76 and a 200 day simple moving average of $2.02. Alector has a twelve month low of $0.87 and a twelve month high of $3.40. The stock has a market cap of $217.21 million, a PE ratio of -1.86 and a beta of 0.64.

Insider Transactions at Alector

In other news, CEO Arnon Rosenthal sold 104,347 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total transaction of $116,868.64. Following the transaction, the chief executive officer directly owned 2,420,040 shares in the company, valued at approximately $2,710,444.80. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Neil Lindsay Berkley sold 37,261 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total transaction of $41,732.32. Following the sale, the chief financial officer directly owned 374,309 shares in the company, valued at $419,226.08. This trade represents a 9.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 196,104 shares of company stock worth $220,064. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Alector

Several hedge funds and other institutional investors have recently made changes to their positions in ALEC. Lexington Partners L.P. bought a new stake in shares of Alector during the third quarter worth $30,000. Pinegrove Venture Partners LLC acquired a new stake in Alector in the third quarter worth about $30,000. Belvedere Trading LLC bought a new stake in Alector during the 3rd quarter worth about $31,000. HBK Sorce Advisory LLC bought a new stake in Alector during the 3rd quarter worth about $34,000. Finally, Savant Capital LLC acquired a new position in Alector during the 3rd quarter valued at about $35,000. 85.83% of the stock is owned by institutional investors and hedge funds.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.